Grade 3 or higher adverse events (regardless of attribution) occurred in 50.7% of the patients in the pembrolizumab group and in 31.6% of the patients in the observation group. The content is ...

She had active metastatic bladder cancer and developed a rash 92 days after the initiation of immunotherapy with pembrolizumab ... of systemic steroids for 4–6 weeks pending clinical improvement to ...

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM) in ...

Our patient received two newer anticancer drugs which were the probable cause of skin rash. Immune checkpoint inhibitors (eg, pembrolizumab ... 7 days of folic acid and 3 days with dexamethasone 4 mg ...

San Francisco, CA (UroToday.com) Pembrolizumab ... All Grade (C4 75%, C5 69%) and Grade 3-5 (C4 26%, C5 24%) adverse events (AEs) were similar as compared to cohorts 1-3 but numerically more frequent.

4 LCCC1520 (NCT02690558) was a multicenter, open label, single arm phase II trial of neoadjuvant pembrolizumab + gemcitabine ... There were 5/41 (12%) patients with any grade adverse events attributed ...

Pembrolizumab plus concurrent chemoradiotherapy demonstrated a higher progression-free survival rate than placebo plus ...

The 5-year results differed little from the 3-year results (84.6% vs 76.4%) in favor of pembrolizumab. "The hazard ratio has remained stable throughout, as most of the recurrence events in triple ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...

Median modified PFS was 9.4 months ... rashes. Withhold or permanently discontinue KEYTRUDA depending on severity.

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...